Leukemia / Lymphoma Clinical Trials

Diseases Treated:

Acute myeloid leukemia (AML)

Eligibility:

• Diagnosis of one of the following:
  • Acute myeloid leukemia (AML)
  • 5% to 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality
  • Myeloid sarcoma
  • High grade myelodysplastic syndrome (MDS) with greater than 5% blasts
  • Treatment-related myeloid neoplasms, including AML and MDS
• 28 days to 21 years old
• No prior therapy, except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine
• Not pregnant

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

• 21 years old or younger
• Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
• Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant

Diseases Treated:

• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myelodysplasia
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Juvenile myelomonocytic leukemia

Eligibility:

For transplant recipient:

• 21 years or younger
• Does not have a suitable sibling donor or volunteer unrelated donor
• Has a suitable single haplotype matched family member donor
• Diagnosed with high risk hematologic malignancy
• No prior allogeneic hematopoietic cell transplant

Diseases Treated:

Leukemia and lymphoma

Eligibility:

• 21 years and younger
• Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
• Has a suitable single haplotype-matched family member donor
• High-risk hematologic malignancy, including certain diagnoses of:
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic myelogenous leukemia (CML)
  • Myelodysplastic syndrome (MDS)
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Younger than 22 years old
• Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

• At least 18 years old
• At least single haplotype matched family member

Recipient eligibility includes:

• 21 years old or younger*
• Diagnosed with relapsed and/or refractory CD19-positive leukemia
• Not suitable for autologous CD19-CAR T-cell therapy

* Initial 3 participants must be at least 16 years old.

Diseases Treated:

• Leukemia
• Lymphoma
• Myeloid sarcoma
• Myelodysplastic syndrome

Eligibility:

• 21 years old and younger
• Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia
  • Myeloid sarcoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Myelodysplastic syndrome (MDS)
  • Non-Hodgkin lymphoma (NHL)
• Has a family member who is a suitable stem cell donor

Diseases Treated:

Leukemia and lymphoma

Eligibility:

• 21 years of age or younger
• Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
• No previous treatment (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation)

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

• Children and young adults up to 21 years old
• Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)

 

 

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

• Newly diagnosed ALL
• 1 year of age or younger at the time of diagnosis
• Has not had any — or has had limited — prior therapy
• Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome

Diseases Treated:

Leukemia and lymphoma

Eligibility:

• Diagnosis of B-cell or T-cell acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy)
• 1 to 18 years old
• No prior therapy or limited prior therapy

Diseases Treated:

Acute myeloid leukemia (AML), acute undifferentiated leukemia, mixed phenotype acute leukemia

Eligibility:

• Diagnosis of relapsed or refractory acute myeloid leukemia (AML), acute undifferentiated leukemia or mixed phenotype acute leukemia 
• At least 2 years old and younger than 22 years old
• Recovered from acute effects of prior therapy and no evidence of graft-versus-host disease (GVHD)
• Adequate liver, kidney and heart functions

Diseases Treated:

Lymphoma

Eligibility:

• Previously untreated CD30+ classical Hodgkin lymphoma
• 21 years or younger at time of diagnosis (low-risk and intermediate-risk patients)
• 25 years or younger (high-risk patients)

Diseases Treated:

Acute Myeloid Leukemia (AML)

Eligibility:

• Younger than 21 years of age
• Diagnosed with recurrent or refractory acute myeloid leukemia (AML)
• Weigh more than 17kg 
• Fully recovered from the acute toxic effects of all prior anti-cancer therapy

Diseases Treated:

Acute lymphoblastic leukemia (ALL)

Eligibility:

• Newly diagnosed ALL
• 1 year of age or younger at the time of diagnosis
• Has not had any — or has had limited — prior therapy
• Does not have mature B-cell ALL, acute myeloid leukemia (AML) or Down syndrome